CTLA4
-
April 4, 2017
Metastatic Melanoma: Not Quite Curable…But Getting There
Emma Shtivelman, PhDBy 2050, the number of deaths due to malignant melanoma in the U.S. could be three times lower than peak levels reached before 1960. Researchers presented the data behind this prediction at the 2017 European Cancer Congress in January. It is unclear how much of this anticipated decline in deaths can be attributed to the availability of new, effective treatments. However, it is obvious… Read more »
-
December 23, 2015
The Growing Arsenal of Immunotherapy Drugs for Melanoma
Emma Shtivelman, PhDLarge numbers of immune cells (T cells in particular) are frequently found within or adjacent to melanoma tumors, indicating that the tumors attract the attention—if not the action—of the immune system. True to its reputation as one of the most ‘immunogenic’ cancers, melanoma now has more U.S. Food and Drug Administration (FDA)-approved immunotherapy (immune system-targeting) drugs than any other cancer type.